Literature DB >> 20091096

Inhibition of C-reactive protein induced expression of matrix metalloproteinases by atorvastatin in THP-1 cells.

Nitin Mahajan1, Veena Dhawan.   

Abstract

The role of CRP as a mediator in atherosclerosis and inflammation is being investigated worldwide. In the present study, the effect of CRP on matrix metalloproteinases (MMP)-1, 2, 9, and their tissue inhibitor (TIMP-1) gene expression in THP-1 monocytic cell line was investigated. Specific mitogen activated protein (MAP) kinase (ERK, p38, and JNK) inhibitors were used to elucidate the signaling pathways involved. Effect of atorvastatin was determined in the presence of CRP on the expression of genes. Time and dose-dependent experiments were performed in the presence of CRP. The results showed that the treatment of THP-1 cells with 100 microg of CRP/ml/10(6) cells for 24 h enhanced the expression of MMPs and TIMP-1 genes significantly. CRP upregulated the expression of these genes via FcgammaRII and utilized ERK signaling pathway to transduce signals. Atorvastatin was able to significantly attenuate CRP-induced MMPs expression and augmented TIMP-1 gene expression significantly. In conclusion, CRP is not only a risk marker for vascular events, but also directly involved in the mechanisms leading to remodeling and destabilization of atherosclerotic plaque. Also, atorvastatin serves as potential therapeutic modality to curb these harmful events.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20091096     DOI: 10.1007/s11010-009-0340-x

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  48 in total

Review 1.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases.

Authors:  Sanjay Kumar; Jeffrey Boehm; John C Lee
Journal:  Nat Rev Drug Discov       Date:  2003-09       Impact factor: 84.694

Review 2.  Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease.

Authors:  Joseph D Raffetto; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2007-07-07       Impact factor: 5.858

Review 3.  C-reactive protein in atherosclerosis: A causal factor?

Authors:  Elaine Paffen; Moniek P M DeMaat
Journal:  Cardiovasc Res       Date:  2006-03-13       Impact factor: 10.787

Review 4.  The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis.

Authors:  A Blum; R Shamburek
Journal:  Atherosclerosis       Date:  2008-09-02       Impact factor: 5.162

Review 5.  The unstable atheroma.

Authors:  R T Lee; P Libby
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-10       Impact factor: 8.311

6.  Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators.

Authors:  V Pasceri; H D Wu; J T Willerson; E T Yeh
Journal:  Circulation       Date:  2000-01-25       Impact factor: 29.690

7.  Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption.

Authors:  I M Loftus; A R Naylor; S Goodall; M Crowther; L Jones; P R Bell; M M Thompson
Journal:  Stroke       Date:  2000-01       Impact factor: 7.914

Review 8.  Do metalloproteinases destabilize vulnerable atherosclerotic plaques?

Authors:  Andrew C Newby
Journal:  Curr Opin Lipidol       Date:  2006-10       Impact factor: 4.776

9.  Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase.

Authors:  M Takata; M Urakaze; R Temaru; K Yamazaki; N Nakamura; Y Nobata; M Kishida; A Sato; M Kobayashi
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

10.  C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo.

Authors:  Sridevi Devaraj; Mohan R Dasu; Uma Singh; L Vijaya Mohan Rao; Ishwarlal Jialal
Journal:  Atherosclerosis       Date:  2008-06-13       Impact factor: 5.162

View more
  2 in total

1.  Phase I/IIa Trial of Atorvastatin in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysm.

Authors:  Adriana H Tremoulet; Sonia Jain; Pei-Ni Jone; Brookie M Best; Elizabeth H Duxbury; Alessandra Franco; Beth Printz; Samuel R Dominguez; Heather Heizer; Marsha S Anderson; Mary P Glodé; Feng He; Robert L Padilla; Chisato Shimizu; Emelia Bainto; Joan Pancheri; Harvey J Cohen; John C Whitin; Jane C Burns
Journal:  J Pediatr       Date:  2019-09-24       Impact factor: 4.406

2.  Short-Term Adjuvant Therapy with Terminalia arjuna Attenuates Ongoing Inflammation and Immune Imbalance in Patients with Stable Coronary Artery Disease: In Vitro and In Vivo Evidence.

Authors:  Divya Kapoor; Dimple Trikha; Rajesh Vijayvergiya; K K Parashar; Deepak Kaul; Veena Dhawan
Journal:  J Cardiovasc Transl Res       Date:  2015-04-01       Impact factor: 4.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.